Krystal Biotech (KRYS) is the lead sponsor of 10 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 4 Phase 2[2], 7 Phase 1[3].
Trial NCT07016750[5] evaluates KB803 in Dystrophic Epidermolysis Bullosa with a target enrollment of 16 participants.
No Form 4 insider filings for KRYS were recorded at the SEC in the past 30 days[6].